Lymphoma Hub Scientific Education Support

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on the SYMPHONY 1 trial (NCT04224493).
 
First, Salles explains the rationale for using tazemetostat, an oral EZH2 inhibitor, with lenalidomide and rituximab in the phase Ib SYMPHONY 1 trial for patients with relapsed/refractory follicular lymphoma. This is followed by an overview of the study design and a review of the adverse effects and response rates. The results of this study have prompted the combination to be further investigated in a phase III trial. 

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).
 
Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter’s transformation.

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma?
Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapies, allogeneic CAR T-cell platforms, alternatives to CD19 CAR T-cell therapies, and combining checkpoint inhibitors with conventional CAR T-cell therapies. 

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d’Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, How do you choose among different BTK inhibitors for treating CLL?
Bosch opens by outlining common BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, noting that comparable efficacy and activity rates can cause difficulty when determining the most appropriate treatment; however, safety profiles vary. Bosch goes on to suggest that other factors, such as patient comorbidities, may be more useful; for example, the varying cardiovascular toxicity of BTK inhibitors may be pertinent when treating patients with comorbid cardiovascular conditions.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Astrid Pavlovsky, FUNDALEU, Buenos Aires, AR. We asked, What are the latest advances in basal PET/CT for Hodgkin and non-Hodgkin lymphoma?
Pavlovsky outlines the progress made in the use of interim positron emission tomography (PET) to guide therapeutic decisions in the last decade, but also notes its limitations, before discussing the latest improvements in basal imaging methods. Pavlovsky goes on to emphasize the prognostic importance of baseline metabolic tumor volume by PET/computerized tomography, especially when combined with interim PET and other parameters such as the International Prognostic Score.

Hosted on Acast. See acast.com/privacy for more information.

As part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem cell transplant in the treatment of diffuse large B-cell lymphoma. Many steering committee members felt that this therapy no longer plays an important role in treatment of the disease.
Hosted on Acast. See acast.com/privacy for more information.